Full Breakdown
Columbia Scientists Achieve Precise Base Editing in Human Embryos, Sparking Ethical Debate
6/5/2026, 9:25:30 PM
Precise Base Editing Achieved in Human Embryos
Scientists at Columbia University applied a base-editing technique to early human embryos, precisely altering the PCSK9 gene linked to cholesterol and the HBG gene involved in fetal hemoglobin. The method avoided the extensive DNA damage seen with earlier CRISPR approaches, though some embryos displayed mosaicism.
From CRISPR to Base Editing: Technical Evolution
CRISPR, introduced in 2012, enabled genome editing but caused off-target cuts and chromosomal loss, evident in 2018 He Jiankui embryo edits and Columbia attempts that damaged the EYS gene. Base editing, created in 2016 by David Liu, changes a single DNA letter without cutting strand, reducing damage.
Researchers, Funders, and Commentators
Lead researcher Dieter Egli directed the Columbia study, with support from Nucleus Genomics, a company that screens IVF embryos. Co-author Nathan Treff is affiliated with the firm. Commentary came from fertility specialist Paula Amato, bioethicist Ana Iltis, and genome-editing pioneer Fyodor Urnov.
Experimental Outcomes and Metrics
The team successfully edited PCSK9 and HBG, achieving dual-gene edits in a subset of embryos without the large-scale DNA loss seen in earlier CRISPR work, which had caused major chromosomal loss in roughly half of tested embryos. Nonetheless, a proportion of the new embryos were mosaic.
Potential Clinical Benefits and Ethical Risks
Proponents argue precise editing could repair disease-causing mutations in IVF embryos, increasing the number of viable embryos for implantation. Critics warn that the same tools could enable non-therapeutic trait selection—Nucleus Genomics already estimates risks for conditions such as heart disease, diabetes, height and intelligence—raising modern eugenics concerns.
Researchers' Public Statements
Egli stressed that the work is not ready for clinical use and urged a public debate, noting scientists can supply data but should leave policy decisions to society. Nucleus Genomics affirmed its commitment to safe embryo screening while declining to comment on therapeutic timelines.
Ethical and Scientific Critiques
Iltis warned that harmful effects may only emerge after birth, urging safety assessments beyond chromosome checks. Urnov questioned the need for editing when IVF screening identifies genetic defects. Nucleus Genomics faced criticism for its 2025 “have your best baby” slogan, viewed as promoting eugenics.
Unresolved Issues and Future Directions
The study is posted online and undergoing journal review, without peer-review validation. U.S. federal policy bars funding for human-embryo research, limiting public support. Researchers plan to reduce mosaicism and evaluate base editing at the ~100-cell stage typical for IVF embryo assessment before any clinical trial.
Direct Voices
- “As a scientist, you can provide the data for discussion, but then essentially there you stop and let others take over.” — Dieter Egli, Geneticist, Columbia University
- “We’re not saying this is going to be used tomorrow in the clinics.” — Dieter Egli, Geneticist, Columbia University
- “The method is promising, but we need to carefully review the final published study.” — Paula Amato, Fertility Specialist, Oregon Health & Science University
- “Some harmful effects might not become apparent until after birth, meaning safety evaluations must go beyond checking for chromosome damage.” — Ana Iltis, Bioethicist, Wake Forest University
